<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="evidence" type="rst"/>
			<rel name="manner" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1004" relname="span">Nonalcoholic fatty liver disease</segment>
<segment id="3" parent="2" relname="elaboration">( NAFLD )</segment>
<segment id="4" parent="1003" relname="same_unit">represents the leading cause of progressive liver disorders worldwide ,</segment>
<segment id="5" parent="1003" relname="elaboration">affecting between 20 % to 40 % of the adult population .</segment>
<segment id="6" parent="1007" relname="span">NAFLD is defined by increased hepatic fat accumulation</segment>
<segment id="7" parent="6" relname="elaboration">not explained by alcohol abuse ,</segment>
<segment id="8" parent="1008" relname="span">and it encompasses a wide spectrum of liver injuries ,</segment>
<segment id="9" parent="1010" relname="span">ranging from simple steatosis</segment>
<segment id="10" parent="9" relname="restatement">( &gt;5 % of liver weight )</segment>
<segment id="11" parent="1011" relname="span">to its inflammatory form nonalcoholic steatohepatitis</segment>
<segment id="12" parent="11" relname="elaboration">( NASH ) .</segment>
<segment id="13" parent="1013" relname="span">NASH may be complicated by the presence of fibrosis</segment>
<segment id="14" parent="1014" relname="span">and , eventually , it may progress to cirrhosis and hepatocellular carcinoma</segment>
<segment id="15" parent="14" relname="elaboration">( HCC ) .</segment>
<segment id="16" parent="1017" relname="joint">NAFLD has a strong inherited component ,</segment>
<segment id="17" parent="1018" relname="span">and variants in proteins regulating hepatocellular lipid handling ,</segment>
<segment id="18" parent="1019" relname="span">including patatin-like phospholipase domain-containing 3</segment>
<segment id="19" parent="18" relname="elaboration">( PNPLA3 ) ,</segment>
<segment id="20" parent="1021" relname="span">transmembrane 6 superfamily member 2</segment>
<segment id="21" parent="20" relname="elaboration">( TM6SF2 ) ,</segment>
<segment id="22" parent="1023" relname="span">membrane bound O-acyltransferase domain-containing 7</segment>
<segment id="23" parent="22" relname="elaboration">( MBOAT7 ) ,</segment>
<segment id="24" parent="1023" relname="elaboration">predispose to the disease development and progression to NASH and fibrosis .</segment>
<segment id="25" parent="1005" relname="joint">Dietary habits such as excessive caloric intake , fructose consumption , and physical inactivity represent other risk factors for NAFLD development .</segment>
<segment id="26" parent="1026" relname="span">In addition , its pathogenesis is closely intertwined with excessive adiposity , insulin resistance</segment>
<segment id="27" parent="26" relname="elaboration">( IR ) , and metabolic syndrome .</segment>
<segment id="28" parent="1005" relname="joint">IR even correlates with the severity of liver fibrosis , the main determinant of NAFLD prognosis .</segment>
<segment id="29" parent="1005" relname="joint">Indeed , fibrosis has been observed in diabetic patients with NAFLD even independently of NASH ,</segment>
<segment id="30" parent="1030" relname="span">and genetic variants</segment>
<segment id="31" parent="1031" relname="span">that impair insulin receptor</segment>
<segment id="32" parent="31" relname="elaboration">( InsR ) signaling favor fibrosis development in NAFLD patients .</segment>
<segment id="33" parent="1033" relname="span">The mechanism</segment>
<segment id="34" parent="1035" relname="span">whereby IR aggravates fibrosis may be related to reduced extracellular matrix</segment>
<segment id="35" parent="34" relname="restatement">( ECM )</segment>
<segment id="36" parent="1036" relname="span">degradation and to the induction of proteins</segment>
<segment id="37" parent="36" relname="elaboration">involved in collagen crosslinking .</segment>
<segment id="38" parent="1038" relname="span">A new perspective of NAFLD pathogenesis and management is provided by epigenetics ,</segment>
<segment id="39" parent="38" relname="elaboration">which modulate transcriptome in response to environmental cues .</segment>
<segment id="40" parent="1042" relname="span">In particular , microRNAs</segment>
<segment id="41" parent="40" relname="elaboration">( miRNAs )</segment>
<segment id="42" parent="1041" relname="same_unit">are short non-protein coding , single-strand RNAs of 19 – 22 nucleotides</segment>
<segment id="43" parent="1043" relname="span">that regulate gene expression and cell-to-cell communication</segment>
<segment id="44" parent="1045" relname="span">as it occurs between hepatocytes and hepatic stellate cells</segment>
<segment id="45" parent="44" relname="restatement">( HSCs )</segment>
<segment id="46" parent="1044" relname="same_unit">during fibrogenesis .</segment>
<segment id="47" parent="1047" relname="span">Alteration of miRNA expression in response to genetic/epigenetic factors or environmental conditions may contribute to steatosis onset and NAFLD progression to fibrosis and cancer ,</segment>
<segment id="48" parent="1048" relname="span">mirroring the histological features and the molecular events</segment>
<segment id="49" parent="48" relname="elaboration">occurring in NAFLD .</segment>
<segment id="50" parent="1050" relname="span">Thus , they could be exploited as attractive candidate biomarkers for an accurate profiling of the different stages of liver injury ,</segment>
<segment id="51" parent="50" relname="elaboration">enabling early and non-invasive diagnosis and the clinical monitoring of the disease progression .</segment>
<segment id="52" parent="1053" relname="span">Therefore , we aimed to explore the mechanisms</segment>
<segment id="53" parent="1054" relname="span">through which epigenetics and environmental factors interact</segment>
<segment id="54" parent="53" relname="purpose">to promote progressive NAFLD in the context of IR .</segment>
<segment id="55" parent="1055" relname="span">To this purpose , we first assessed</segment>
<segment id="56" parent="1056" relname="span">which miRNAs were deregulated by IR in HSCs</segment>
<segment id="57" parent="56" relname="elaboration">whose activation represents the hallmark of liver fibrosis .</segment>
<segment id="58" parent="1059" relname="attribution">Secondly , we evaluated</segment>
<segment id="59" parent="1059" relname="span">whether the miRNAs differentially expressed in insulin resistant HSCs could impact on NAFLD-related fibrosis</segment>
<segment id="60" parent="59" relname="means">by using an experimental model of IR-NASH .</segment>
<segment id="61" parent="1062" relname="span">Thus ,</segment>
<segment id="62" parent="1063" relname="span">to investigate the independent contribution of IR and NASH</segment>
<segment id="63" parent="62" relname="elaboration">that is usually intertwined in patients on miRNAs expression ,</segment>
<segment id="64" parent="1065" relname="span">IR was induced in mice by haploinsufficiency for InsR</segment>
<segment id="65" parent="64" relname="elaboration">( InsR+/− ) ,</segment>
<segment id="66" parent="1066" relname="span">which determines an impairment of hepatic insulin signaling recapitulating</segment>
<segment id="67" parent="66" relname="elaboration">that has been observed in NAFLD patients .</segment>
<segment id="68" parent="1068" relname="span">Conversely ,</segment>
<segment id="69" parent="1070" relname="span">to model fibrogenic NASH , we exploited the methionine choline deficient</segment>
<segment id="70" parent="69" relname="restatement">( MCD )</segment>
<segment id="71" parent="1071" relname="span">diet ,</segment>
<segment id="72" parent="1072" relname="span">which impairs phospholipid metabolism</segment>
<segment id="73" parent="72" relname="manner">without altering IR .</segment>
<segment id="74" parent="1075" relname="span">Finally , we tested the expression of the candidate miRNAs in immortalized human hepatoma cells</segment>
<segment id="75" parent="74" relname="elaboration">( HepG2 )</segment>
<segment id="76" parent="1077" relname="span">and in HSCs</segment>
<segment id="77" parent="76" relname="restatement">( LX-2 )</segment>
<segment id="78" parent="1076" relname="same_unit">in the presence or absence of miRNA mimics .</segment>
<segment id="79" parent="1080" relname="attribution">Here , we showed</segment>
<segment id="80" parent="1080" relname="span">that miR-101-3p was downregulated in InsR+/− HSCs and hepatocytes ,</segment>
<segment id="81" parent="1081" relname="joint">its expression was reduced even in total livers of insulin resistant mice ,</segment>
<segment id="82" parent="1081" relname="joint">and it was associated with all stages of liver disease .</segment>
<segment id="83" parent="1083" relname="same_unit">Consistently with these results ,</segment>
<segment id="84" parent="1085" relname="attribution">target prediction analysis revealed</segment>
<segment id="85" parent="1085" relname="span">that miR-101-3p is involved in insulin signaling , lipid metabolism , cell proliferation , fibrogenesis , and cancer susceptibility ,</segment>
<segment id="86" parent="85" relname="elaboration">possibly representing a molecular signature in NAFLD during IR .</segment>
<segment id="87" parent="1086" relname="span">Furthermore , miR-101-3p overexpression in HepG2 and LX-2 reduced proliferation , migration , and invasiveness ,</segment>
<segment id="88" parent="87" relname="elaboration">regulating pro-fibrotic and pro-carcinogenic markers .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1005" relname="background"/>
<group id="1003" type="multinuc" parent="1002" relname="span"/>
<group id="1004" type="span" parent="1003" relname="same_unit"/>
<group id="1005" type="multinuc" parent="1001" relname="span"/>
<group id="1007" type="span" parent="1005" relname="joint"/>
<group id="1008" type="span" parent="1005" relname="joint"/>
<group id="1009" type="span" parent="8" relname="elaboration"/>
<group id="1010" type="span" parent="1009" relname="span"/>
<group id="1011" type="span" parent="1010" relname="purpose"/>
<group id="1013" type="span" parent="1005" relname="joint"/>
<group id="1014" type="span" parent="13" relname="elaboration"/>
<group id="1016" type="span" parent="1005" relname="joint"/>
<group id="1017" type="multinuc" parent="1016" relname="span"/>
<group id="1018" type="span" parent="1017" relname="joint"/>
<group id="1019" type="span" parent="17" relname="elaboration"/>
<group id="1020" type="multinuc" parent="1017" relname="evidence"/>
<group id="1021" type="span" parent="1020" relname="same_unit"/>
<group id="1022" type="span" parent="1020" relname="same_unit"/>
<group id="1023" type="span" parent="1022" relname="span"/>
<group id="1026" type="span" parent="1005" relname="joint"/>
<group id="1030" type="span" parent="1005" relname="joint"/>
<group id="1031" type="span" parent="30" relname="elaboration"/>
<group id="1033" type="span" parent="1005" relname="joint"/>
<group id="1034" type="multinuc" parent="33" relname="elaboration"/>
<group id="1035" type="span" parent="1034" relname="same_unit"/>
<group id="1036" type="span" parent="1034" relname="same_unit"/>
<group id="1038" type="span" parent="1005" relname="joint"/>
<group id="1040" type="span" parent="1005" relname="joint"/>
<group id="1041" type="multinuc" parent="1040" relname="span"/>
<group id="1042" type="span" parent="1041" relname="same_unit"/>
<group id="1043" type="span" parent="1041" relname="elaboration"/>
<group id="1044" type="multinuc" parent="43" relname="circumstance"/>
<group id="1045" type="span" parent="1044" relname="same_unit"/>
<group id="1047" type="span" parent="1005" relname="joint"/>
<group id="1048" type="span" parent="47" relname="elaboration"/>
<group id="1050" type="span" parent="1005" relname="joint"/>
<group id="1052" type="span" parent="1005" relname="joint"/>
<group id="1053" type="span" parent="1052" relname="span"/>
<group id="1054" type="span" parent="52" relname="elaboration"/>
<group id="1055" type="span" parent="1053" relname="purpose"/>
<group id="1056" type="span" parent="55" relname="elaboration"/>
<group id="1057" type="multinuc" parent="1005" relname="joint"/>
<group id="1058" type="span" parent="1057" relname="sequence"/>
<group id="1059" type="span" parent="1058" relname="span"/>
<group id="1060" type="multinuc" parent="1057" relname="sequence"/>
<group id="1061" type="multinuc" parent="1060" relname="joint"/>
<group id="1062" type="span" parent="1061" relname="same_unit"/>
<group id="1063" type="span" parent="61" relname="purpose"/>
<group id="1064" type="span" parent="1061" relname="same_unit"/>
<group id="1065" type="span" parent="1064" relname="span"/>
<group id="1066" type="span" parent="1065" relname="elaboration"/>
<group id="1067" type="multinuc" parent="1060" relname="joint"/>
<group id="1068" type="span" parent="1067" relname="sequence"/>
<group id="1069" type="multinuc" parent="68" relname="purpose"/>
<group id="1070" type="span" parent="1069" relname="same_unit"/>
<group id="1071" type="span" parent="1069" relname="same_unit"/>
<group id="1072" type="span" parent="71" relname="elaboration"/>
<group id="1073" type="span" parent="1067" relname="sequence"/>
<group id="1074" type="multinuc" parent="1073" relname="span"/>
<group id="1075" type="span" parent="1074" relname="same_unit"/>
<group id="1076" type="multinuc" parent="1074" relname="same_unit"/>
<group id="1077" type="span" parent="1076" relname="same_unit"/>
<group id="1078" type="multinuc" parent="1074" relname="elaboration"/>
<group id="1079" type="span" parent="1078" relname="joint"/>
<group id="1080" type="span" parent="1079" relname="span"/>
<group id="1081" type="multinuc" parent="80" relname="elaboration"/>
<group id="1082" type="multinuc" parent="1078" relname="joint"/>
<group id="1083" type="multinuc" parent="1082" relname="joint"/>
<group id="1084" type="span" parent="1083" relname="same_unit"/>
<group id="1085" type="span" parent="1084" relname="span"/>
<group id="1086" type="span" parent="1082" relname="joint"/>
	</body>
</rst>
